Products

Pillar oncoReveal Solid Tumor v2 Panel

Robust DNA NGS assay interrogating 48 genes across multiple solid tumor cancer types.

Pillar oncoReveal Solid Tumor v2 Panel

Robust DNA NGS assay interrogating 48 genes across multiple solid tumor cancer types.

48 hours from sample to report

Assay time

~3 hr

Hands-on time

20–80 ng DNA

Input quantity

See full details in the specifications table

Overview

The Pillar oncoReveal Solid Tumor v2 Panel is a robust 48-gene assay that simultaneously tests for key mutations present in DNA from solid tumors, including non-small cell lung cancer (NSCLC), colorectal, melanoma, endometrial, pancreatic, gastrointestinal stromal tumor (GIST), bladder, thyroid, and gliomas from formalin-fixed, paraffin-embedded (FFPE) samples. Additionally, genes with potential importance in immuno-oncology such as POLD1 and POLE are analyzed.

Key features

  • Access a rapid workflow to go from sample to report within 48 hours

  • Achieve variant detection as low as 1% VAF without UIDs even with limited DNA input or poor sample quality 

  • Improve lab efficiency and reduce “no calls” 

The panel is designed to detect single nucleotide variants (SNVs) and insertion/deletions (indels) in DNA isolated from FFPE tissue.

The assay uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.

The workflow allows labs to maintain control of samples and results with single-tube, tiled amplification that can be performed in-house by any NGS lab.

Specifications

Assay time 48 hours from sample to report
Cancer type Pan-cancer, Solid tumor
Content specifications 48 genes
Description The Pillar oncoReveal Solid Tumor v2 Panel is a robust DNA NGS assay, interrogating 48 genes across multiple solid tumor cancer types.
Hands-on time ~3 hr
Input quantity 20–80 ng DNA
Instruments MiSeq System, iSeq 100 System, NextSeq 550 System, MiSeqDx in Research Mode, MiniSeq System, NextSeq 550Dx in Research Mode, MiSeq i100 System
Mechanism of action Multiplex PCR using tiled amplicon
Method Targeted DNA sequencing, Amplicon sequencing
Nucleic acid type DNA
Number of amplicons Pool 1: 246 amplicons
Number of reactions 24 reactions per kit
On-target reads 98%
Specialized sample types FFPE tissue
Species category Human
Target insert size 154 bp
Technology Sequencing
Uniformity 98%
Variant class Single nucleotide variants (SNVs), Insertions-deletions (indels)

Required Products

Pillar oncoReveal Solid Tumor v2 Panel also requires the use of a Pillar index kit, sequencing reagents, and DRAGEN Amplicon or PiVAT secondary analysis software. If additional variant interpretation is desired, Illumina Connected Insights is recommended.

/ Results

Applications

Pillar oncoReveal Solid Tumor v2 Panels also requires the use of a Pillar index kit, sequencing reagents, and DRAGEN Amplicon or PiVAT secondary analysis software. If additional variant interpretation is desired, Illumina Connected Insights is recommended.

Example workflow

1
Prep

Pillar oncoReveal Solid Tumor v2 Panel

2
Sequence
3
Analyze

Related applications and methods

FFPE sequencing

Explore optimized workflows and technologies that facilitate sequencing and microarray applications for challenging FFPE samples.

Advancing cancer research through NGS

Our sequencing and microarray technologies support a broad range of cancer genomics research applications, from DNA to RNA analysis, epigenetics, and more.

Documentation

Product literature
Support documentation

A dedicated support section is not currently available for this product

Compare

Pillar oncoReveal Solid Tumor v2 Panel TruSight Oncology 500 Pillar oncoReveal Multi-Cancer CNV + RNA Fusion Panel Pillar oncoReveal Multi-Cancer RNA Fusion v2 Panel
Assay time 48 hours from sample to report 4–5 days from sample to results 48 hours from sample to report 48 hours from sample to report
Content specifications 48 genes Targeted sequencing of DNA from 523 genes and RNA from 55 genes for a total of 1.94 Mb panel size. MSI and TMB measurement included.  The optional TruSight Oncology 500 HRD kit (not available in Japan) content includes coverage of ~25K SNPs to assess homologous recombination deficiency through a comprehensive genomic instability score (LOH+TAI+LST) powered by Myriad Genetics.  78- gene small pan-tumor oncology panel 18 driver genes and 83 fusion partners
Description The Pillar oncoReveal Solid Tumor v2 Panel is a robust DNA NGS assay, interrogating 48 genes across multiple solid tumor cancer types. Assay that enables comprehensive genomic profiling from FFPE tissue and runs on the NextSeq 550 System or NextSeq 550Dx Instrument (in Research Mode) and can batch up to eight samples at a time. 78- gene amplicon-based panel with DNA & RNA content, simple single tube workflow RNA fusion panel interrogating 18 driver genes and 83 fusion partners from FFPE tissue
Hands-on time ~3 hr ~2.5 hr for automated workflow
~10.5 hr for manual workflow 		~3 hr ~3 hr
Input quantity 20–80 ng DNA 40 ng DNA and/or 40 ng RNA 5–80 ng DNA, 10–50 ng RNA 10–50 ng RNA
Method Targeted DNA sequencing, Amplicon sequencing Targeted DNA sequencing, Targeted RNA sequencing, Target enrichment Targeted DNA sequencing, Amplicon sequencing, Targeted RNA sequencing Amplicon sequencing, Targeted RNA sequencing
Nucleic acid type DNA DNA, RNA DNA, RNA RNA
Number of reactions 24 reactions per kit 24 DNA/24 RNA 24 reactions per kit
On-target reads 98% 99.5% ± 0.1%
Specialized sample types FFPE tissue FFPE tissue Blood, Low-input samples, FFPE tissue FFPE tissue
Species category Human Human Human Human
Target insert size 154 bp Average: 120 bp (range 86-185 bp) 120 bp

Selection tools:

Library Prep and Array Kit Selector

Find the right sequencing library preparation kit or microarray for your needs. Filter by method, species, and more. Compare, share, and order kits.

Figures

Gene List

Pillar oncoReveal Solid Tumor v2 Panel includes 48 genes.

Panel Specifications

Pillar oncoReveal Solid Tumor v2 Panel specifications for interrogation DNA isolated from FFPE tissue.

Library prep (3)

OncoReveal Solid Tumor Panel v2 24 Rxn

HDA-CH-3003-24

48 gene (24 sample) solid tumor DNA panel on SLIMamp™ workflow

Sign in to add to cart or see pricing.

List Price:

Discounts:

Indices PI501-8, PI701-4 (32 combinations, 96 reactions)

IDX-PI-1001-96

Indices PI501-8, PI701-4 (32 combinations, 96 reactions)

Sign in to add to cart or see pricing.

List Price:

Discounts:

Kit D, indices PI501-8, PI701-12

IDX-PI-1004-192

Kit D, indices PI501-8, PI701-12

Sign in to add to cart or see pricing.

List Price:

Discounts:

Showing of

Selection summary

Product

Qty

Unit price

Total ( items)

You have not selected any items yet.

Please add these products to your cart before leaving the page to avoid losing them.

Order the MiSeq i100 Series

Simplified operations, advanced chemistry, and onboard informatics provide an easy-to-use, fast, and flexible instrument supporting a broad range of applications.

MiSeq i100 Series Reagent Kits

Reagents for the MiSeq i100 Series feature easy-to-use cartridges and multiple flow cell configurations for flexible sequencing options.

Illumina Connected Analytics ordering

Operationalize informatics and drive scientific insights with Illumina Connected Analytics. Contact us for information on pricing, subscriptions, and more.

TruSight Oncology 500

Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI, and HRD) from FFPE tissue.

TruSight Oncology 500 ctDNA v2

Enable CGP with a pan-cancer panel capable of detecting key IO gene signatures (TMB, MSI) plus all main variant classes from ctDNA in blood plasma.

Pillar oncoReveal Essential MPN Panel

A robust assay targeting key mutations in MPL, JAK2, and CALR genes, utilizing single-tube SLIMamp workflow for fast library prep and turnaround time.

Speak with a specialist

Reach out for information about our products and services, or get answers to questions about our technology.